Plantar Fascia Embolization for the Treatment of Chronic Plantar Fasciitis: A Critical Appraisal of Limited Evidence

Abstract

Background: Plantar fascia embolization (PFE) has emerged as a minimally invasive intervention for patients with chronic plantar fasciitis. Increasing visibility of this procedure has led to growing patient and clinician interest despite a limited evidentiary foundation. Methods: A critical review of the available literature was performed to evaluate the quality of evidence, patient selection criteria, procedural variability, reported outcomes, and clinical applicability of PFE. Results: Current evidence is limited to small, uncontrolled observational studies. While improvements in pain and function have been reported, consistent limitations include a lack of standardized diagnostic criteria, the absence of comparator groups, variability in prior conservative treatment, non-blinded outcome assessment, and incomplete biomechanical characterization. Conclusions: Although early findings are encouraging, the current evidence base is insufficient to define the efficacy, safety, or appropriate clinical role of PFE. At present, this intervention should be considered investigational, and further study using standardized diagnostic and treatment frameworks is required.

1. Introduction

Plantar fasciitis is the most common cause of plantar heel pain, accounting for a substantial proportion of foot and ankle-related outpatient visits [1]. The condition is typically characterized by focal pain at the medial calcaneal tubercle, most prominent with initial steps after periods of rest. Most patients improve with conservative measures, including activity modification, stretching, orthoses, night splints, physical therapy, and judicious use of injections. Published series suggest that approximately 90% of patients experience symptom resolution within several months of nonoperative management [2]. Surgical intervention is generally reserved for a small subset of patients with persistent, well-documented symptoms despite prolonged, structured conservative care [3].

In recent years, plantar fascia embolization (PFE) has emerged as a proposed minimally invasive intervention for patients with persistent plantar heel pain. This technique, primarily developed within interventional radiology, is based on the hypothesis that abnormal neovascularization and associated neoinnervation contribute to pain generation in chronic plantar fasciopathy.

As awareness of PFE increases, podiatric physicians are increasingly asked to evaluate its appropriateness, counsel patients, and coordinate care with other specialists. Even if the procedure is currently performed primarily by interventional radiologists, podiatrists remain central to the diagnosis of plantar heel pain, the delivery and optimization of conservative care, and the determination of whether symptoms are truly refractory.

Given this clinical position, podiatric clinicians need a clear understanding of both the proposed rationale for this intervention and the limitations of the current literature. This review critically evaluates the available evidence on PFE, with the goal of providing a balanced, clinically relevant framework to guide patient counseling, clinical decision-making, and future investigation.

1.1. Rationale for Review

The increasing visibility of PFE, its promotion as a minimally invasive option for chronic heel pain, and the absence of established podiatric guidance prompted the authors to address the following question: Is there sufficient evidence to support the use of plantar fascia embolization in the treatment of plantar fasciitis?

This review was undertaken to evaluate the quality of available evidence, the consistency of diagnostic criteria, the adequacy of prior treatment algorithms, the biological plausibility of the proposed mechanism of action, and the relevance of the current literature to podiatric clinical practice.

1.2. Nomenclature

At present, there is no standardized nomenclature for arterial embolization procedures performed for plantar fasciitis. In other musculoskeletal conditions, such as knee osteoarthritis, accepted terminology has evolved around clearly defined target vessels, such as genicular artery embolization, reflecting relative anatomic consistency, procedural standardization, and a more mature evidence base.

In contrast, embolization procedures described for plantar fasciitis involve variable techniques and target different arterial territories, including the posterior tibial artery, the medial calcaneal branches, and the plantar branches, using catheter-based or needle-based approaches under fluoroscopic or ultrasound guidance. As a result, a vessel-specific naming convention analogous to genicular artery embolization is not currently applicable.

The term plantar fascia embolization has nevertheless emerged in nonacademic contexts as a simplified descriptor, particularly in marketing and patient-facing materials. For clarity and consistency within this review, the term PFE is used as a collective shorthand to refer to arterial embolization procedures performed for the indication of plantar fasciitis, without implying procedural standardization or endorsement of the technique.

2. Methods

A literature search was conducted using MEDLINE, PubMed, and EMBASE for English-language publications evaluating embolization techniques for plantar fasciitis. Reference lists of relevant articles were reviewed to identify additional studies. Articles were assessed for study design, patient selection criteria, diagnostic confirmation of plantar fasciitis, description of prior treatments, outcome measures, follow-up duration, and adverse event reporting.

Evidence was categorized using a four-tier classification system for therapeutic studies, ranging from randomized controlled trials with masked outcome assessment (Class I) to uncontrolled case series and expert opinion (Class IV).

3. Results

3.1. Overview of Identified Studies

The available literature on PFE remains limited. Four clinical studies were identified and included in the review, including three studies available at the time of initial submission and one recently published prospective case series [4,5,6,7]. No randomized controlled trials were identified. All identified studies fall into Class IV evidence, characterized by the absence of randomization, control groups, or blinded outcome assessment.

The largest and most frequently cited study is a retrospective, single-arm series of 66 patients treated at specialty musculoskeletal intervention clinics in Japan [4]. Additional publications consist of small prospective single-arm studies and feasibility reports [5,6,7]. These studies report favorable short-term outcomes; however, attribution of improvement to the intervention alone remains uncertain.

3.2. Study-Specific Analysis of Included Literature

Sasaki et al. [4] reported a retrospective series of 66 patients undergoing ultrasound-guided intra-arterial embolization of abnormal neovessels, with a mean follow-up of 30.9 months. The study demonstrated improvement in American Orthopedic Foot and Ankle Society (AOFAS) scores from 65.8 before treatment to 92.8 at 1 year, with reported maintenance of benefit at final follow-up and no major adverse events. Strengths of this study include its relatively larger sample size and longer follow-up duration compared with other available reports. However, the retrospective design, lack of comparator group, potential selection bias, and absence of standardized diagnostic and treatment algorithms limit the ability to draw definitive conclusions regarding efficacy.

Tonkaz and Bekci [5] conducted a prospective, single-arm cohort study of 32 patients undergoing superselective embolization of the medial calcaneal artery. Significant improvements were reported in visual analog scale (VAS) pain scores from 7.3 to 1.3, and Foot Function Index (FFI) scores from 55.5 to 20.4, along with a reduction in plantar fascia thickness. While the prospective design strengthens internal validity relative to retrospective series, the absence of a control group, short follow-up, and non-blinded outcome assessment introduces substantial risk of bias. In addition, a recurrence rate of 15.6% was reported and managed conservatively.

Gandhi and Banker [6] presented a prospective feasibility study of 10 patients treated with transcatheter arterial embolization using imipenem/cilastatin. The study reported a 100% technical success rate, with no reported pain relapse or need for additional therapy at 6 months. However, the very small sample size, lack of control or sham group, short follow-up, and high risk of placebo and natural history effects significantly limit interpretability and generalizability.

Gill et al. [7] reported short-term outcomes from a prospective case series evaluating transcatheter arterial embolization for plantar heel pain. Although the study adds additional prospective data and suggests symptomatic improvement at 6 months, it remains limited by a small sample size, a lack of a comparator group, and short-term follow-up. Accordingly, it does not materially alter the overall level of evidence supporting PFE.

Taken together, these studies suggest potential short-term symptomatic improvement, but they are uniformly limited by a lack of controls, heterogeneity in patient selection and technique, and an inability to isolate the treatment effect from natural history, placebo response, regression to the mean, or concurrent treatments.

3.3. Diagnostic Criteria and Patient Selection

A central limitation across studies is the lack of rigorous, standardized diagnostic confirmation of plantar fasciitis. In the largest series, inclusion criteria consisted of localized heel tenderness, plantar fascia thickness greater than 4 mm on ultrasound, and persistence of symptoms after at least 2 months of conservative treatment [4].

While these criteria may be suggestive of plantar fasciitis, they do not systematically exclude other causes of plantar heel pain, including calcaneal stress fractures, Baxter nerve entrapment, fat pad atrophy, inflammatory arthropathies, and referred pain from proximal neuropathic sources.

Notably absent is confirmation using a comprehensive diagnostic framework commonly employed in clinical trials of plantar fasciitis, which often requires longer symptom duration, standardized clinical examination findings, and exclusion of competing diagnoses.

3.4. Adequacy of Prior Conservative Treatment

Another significant limitation is the lack of an algorithmic, standardized conservative treatment pathway before enrollment. In the largest study, patients were included after as little as 2 months of conservative care, and a substantial proportion were treated within 6 months of symptom onset.

This is particularly relevant given the well-documented natural history of plantar fasciitis, in which the majority of patients improve with time and nonoperative care alone. Without a uniform requirement for prolonged, structured conservative management, it is not possible to determine whether observed improvements reflect treatment effect, natural history, placebo response, regression to the mean, or optimization of concurrent care.

3.5. Outcomes and Follow-Up

Reported outcomes include improvements in pain scores and functional indices such as the AOFAS score. However, these measures were collected without blinding and, in some cases, rely on instruments whose validity and sensitivity have been questioned in the foot and ankle literature. Additionally, patients were permitted to continue other treatments during follow-up in some reports, further confounding attribution of benefit to embolization alone.

The current literature provides preliminary observations rather than definitive evidence of efficacy. These findings should be interpreted cautiously, given the inherent limitations of uncontrolled observational data.

3.6. Safety Reporting

Short-term adverse events reported include transient skin discoloration, localized hematoma, urticaria, and temporary sensory symptoms. No major ischemic complications were reported in the published series. However, given the limited sample sizes and absence of comparative groups, the true incidence of uncommon but clinically meaningful complications cannot be reliably estimated.

Longer-term safety, durability of symptom relief, and potential effects of embolization on adjacent soft tissue and osseous structures remain incompletely characterized.

3.7. Procedural Overview

PFE is typically performed by interventional radiologists using catheter-based techniques. Vascular access is obtained via standard arterial approaches, followed by selective catheterization of branches of the posterior tibial artery, including medial calcaneal and plantar branches.

Angiographic imaging is used to identify areas of increased vascularity, which are presumed to correlate with pathologic neovascularization. Embolic agents, most commonly imipenem/cilastatin or similar particulate materials, are delivered in a superselective manner to temporarily reduce perfusion to these regions.

However, there is substantial variability in technique across reported studies, including differences in target vessels, embolic materials, imaging modalities, and procedural endpoints. This lack of standardization limits reproducibility and complicates the interpretation of clinical outcomes.

3.8. Pathophysiology and Mechanistic Considerations

The proposed mechanism of PFE centers on the concept that abnormal neovascularization and associated nerve ingrowth are primary drivers of pain in plantar fasciitis. While neovascularity has been observed in some chronic enthesopathies, its role in plantar fasciitis remains uncertain.

Seminal histopathologic work by Lemont et al. [8] demonstrated that plantar fasciitis is characterized predominantly by degenerative changes, including collagen disorganization, fibroblast proliferation, and microtearing at the enthesis, with minimal evidence of classic inflammation. These findings challenge the assumption that vascular-targeted interventions directly address the underlying pathology of the condition.

Furthermore, it remains unclear whether neovascularization observed on imaging represents a causative process, a secondary response to tissue degeneration, or an epiphenomenon without direct relevance to symptom generation. Evidence derived from embolization studies in other anatomic sites or disease processes, including knee osteoarthritis [9,10], frozen shoulder [11,12], and tendinopathies and enthesopathies [13,14], should therefore not be considered direct evidence of efficacy for plantar fasciitis.

3.9. Biomechanical Considerations in Refractory Plantar Fasciitis

A notable limitation of the current literature is the absence of meaningful biomechanical evaluation. Plantar fasciitis is widely understood to be a mechanically driven condition, influenced by factors such as equinus, altered load distribution, and compensatory foot mechanics.

None of the available studies systematically assesses ankle dorsiflexion, subtalar joint function, forefoot loading patterns, gait mechanics, or the adequacy and optimization of orthotic therapy. This omission is clinically relevant. Failure of initial conservative treatment does not necessarily indicate failure of appropriately optimized biomechanical management. Variability in orthotic design, fit, and modification can significantly influence outcomes.

Without addressing these factors, it remains unclear whether patients undergoing embolization have received comprehensive conservative care or whether the designation of refractory plantar fasciitis is premature. This limitation is particularly important for podiatric clinicians, who are often responsible for determining whether conservative treatment has truly failed.

3.10. External Validity and Generalizability

The largest body of data supporting PFE originates from a limited number of centers within a single country. Differences in health-care delivery, referral patterns, thresholds for intervention, access to physical therapy or orthotic care, and patient expectations may introduce selection bias that limits direct extrapolation to practice in the United States or Europe.

In addition, current studies do not define a reproducible podiatric treatment pathway before referral for embolization. This further limits generalizability to clinical settings in which structured conservative care and biomechanical optimization are standard components of management.

4. Discussion

The available evidence evaluating PFE for the treatment of plantar fasciitis remains limited in both quantity and quality. All currently published studies are Level IV evidence, consisting of uncontrolled observational series without randomization, comparator groups, or blinded outcome assessment. While reported improvements in pain and function are encouraging, the absence of methodological safeguards limits the ability to attribute these outcomes directly to the intervention.

A consistent limitation across studies is the lack of standardized diagnostic criteria. Inclusion is typically based on clinical heel pain with imaging findings such as increased plantar fascia thickness, but without a comprehensive framework to exclude alternative or coexisting causes of plantar heel pain. Conditions such as fat pad atrophy, calcaneal stress injury, Baxter nerve entrapment, inflammatory arthropathy, and proximal neuropathic sources are not systematically addressed. This introduces uncertainty regarding the true pathology being treated.

Similarly, there is substantial variability and a lack of standardization in prior conservative management. In several studies, patients were enrolled after relatively short durations of nonoperative care, sometimes as little as 2 months. Given the well-established natural history of plantar fasciitis, in which the majority of patients improve over time with conservative treatment, observed improvements may reflect natural disease progression, placebo response, regression to the mean, or concurrent care rather than a true treatment effect.

Outcome assessment also presents challenges. Reported improvements in VAS scores and functional measures are not obtained under blinded conditions and may be influenced by patient expectation or concurrent treatments. In some studies, patients continued additional therapies during follow-up, further confounding interpretation.

Despite these limitations, it is important to recognize that PFE represents an evolving intervention with early signals of potential benefit. The procedure appears technically feasible, and reported short-term safety profiles are acceptable within the confines of small observational cohorts. However, the current literature provides preliminary observations rather than definitive evidence of efficacy.

For podiatric clinicians, the relevance of this topic lies in patient evaluation and counseling. As awareness of PFE increases, patients may seek guidance regarding its role in management. At present, the absence of standardized diagnostic criteria, clearly defined indications, comprehensive biomechanical assessment, and high-level comparative data limits the ability to recommend this intervention as part of routine clinical care.

Proposed Clinical and Research Framework

To better define the potential role of PFE, future studies should incorporate a structured clinical framework addressing the key gaps identified in the current literature.

Diagnostic criteria should include characteristic history, focal physical examination findings localized to the plantar medial calcaneal tubercle, imaging confirmation when appropriate, and systematic exclusion of alternative diagnoses.

Refractory plantar fasciitis should be defined by failure of a structured, adequately dosed conservative treatment program. This should include gastrocnemius-soleus stretching, activity modification and load management, physical therapy when appropriate, night splints or other adjunctive measures as indicated, and orthotic intervention with appropriate customization and adjustment. A minimum duration of 6 to 12 months of structured care should be considered before procedural intervention is studied or recommended.

Given the multifactorial nature of plantar heel pain, future investigations should include biomechanical assessment, including ankle dorsiflexion, subtalar and midfoot mechanics, forefoot loading patterns, and orthotic optimization before procedural consideration.

Study design should include appropriate comparator groups where feasible, including optimized nonoperative care. Randomized controlled trials may present logistical and ethical challenges, but prospective comparative cohort studies, registry-based outcome tracking, standardized treatment protocols across centers, independent outcome assessment, validated patient-centered outcome measures, and longer-term follow-up would substantially improve the quality and clinical applicability of available evidence.

Such an approach would allow for more meaningful evaluation of treatment effects, safety, durability, and patient selection while allowing innovation to proceed within a clinically responsible framework.

5. Conclusions

Plantar fascia embolization represents an emerging intervention with early reports of symptomatic improvement. However, the current body of evidence is limited to small, uncontrolled studies with significant methodological variability and risk of bias.

At present, there is insufficient high-quality evidence to establish the efficacy, safety, or appropriate clinical role of this procedure. Accordingly, PFE should be considered investigational and should not be routinely recommended outside carefully selected or research-based settings.

For podiatric physicians, awareness of this procedure is important, as patients may increasingly inquire about or be referred for this intervention. A clear understanding of the current evidence allows for informed discussion and appropriate guidance while higher-quality data are being developed.